Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands …

[Read more...] about Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in …

[Read more...] about Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Video webcast now available here TAMPA, FL and LONDON – August 27, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …

[Read more...] about Akari Therapeutics Participates in the Virtual Investor “Why Now” On-Demand Conference